drugset / Trial / NCT03570918
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Phase 1
Completed
21 enrolled
MacroGenics
National Institute of Allergy and Infectious Diseases (NIAID) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
Timeline
- Start
- 2018-09-25
- Primary completion
- 2021-09-28
- Completion
- 2021-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MGD014 | Other / unclassified | 0.1 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 0.3 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 1 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 3 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 10 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 30 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 100 ug/kg | Other |
| Subject | MGD014 | Other / unclassified | 300 ug/kg | Other |